Even as fears of another Covid wave have come to dominate public discourse, Bharat Biotech’s intranasal vaccine iNcovacc, which got the government’s nod for restricted use in emergency situations among people in the age group of 18 and above for a primary two-dose schedule, is yet to be included in CoWin, the central vaccination app.

The price of the vaccine has to be fixed in dialogue with the Government, but only after it is included in the application, sources in the company told businessline.

Informed sources said that the company has requested the Government to expedite the issue.

iNcovacc is a recombinant replication-deficient adenovirus vectored vaccine, with a pre-fusion stabilised spike protein.

Apart from intranasal vaccines, use of Covaxin in children in the age group of 6-12, which was approved in April this year, has not been followed up by the Government, as it has not been included in this category in CoWIN so far.

Related Stories
Covid-19: Emergency use authorisation granted to Bharat Bio’s nasal vaccine
The nasal vaccine can be taken six months after the second dose